Discovery of ovarian cancer biomarkers in serum using NanoLC electrospray ionization TOF and FT-ICR mass spectrometry

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Treatment of cancer patients is greatly facilitated by detection of the cancer prior to metastasis. One of the obstacles to early cancer detection is the lack of availability of biomarkers with sufficient specificity. With modern differential proteomic techniques, the potential exists to identify high specificity cancer biomarkers. We have delineated a set of protocols for the isolation and identification of serum biomarkers for ovarian cancer that exist in the low molecular weight serum fraction. After isolation of the low molecular weight fraction by ultrafiltration, the potential biomarkers are separated by reversed phase nano liquid chromatography. Detection via TOF or FT-ICR yields a data set for each sample. We compared stage III/TV ovarian cancer serum with postmenopausal age-matched controls. Using bioinformatics tools developed at Mayo, we normalized each sample for intensity and chromatographic alignment. Normalized data sets are subsequently compared and potential biomarkers identified. Several candidate biomarkers were found. One of these contains the sequence of fibrinopeptide-A known to be elevated in many types of cancer including ovarian cancer. The protocols utilized will be examined and would be applicable to a wide variety of cancers or disease states.

Original languageEnglish (US)
Pages (from-to)239-249
Number of pages11
JournalDisease Markers
Volume19
Issue number4-5
StatePublished - 2003

Fingerprint

Electrospray ionization
Biomarkers
Tumor Biomarkers
Ovarian Neoplasms
Mass spectrometry
Mass Spectrometry
Serum
Neoplasms
Molecular Weight
Molecular weight
Fibrinopeptide A
Liquid chromatography
Ultrafiltration
Reverse-Phase Chromatography
Bioinformatics
Computational Biology
Early Detection of Cancer
Proteomics
Availability
Neoplasm Metastasis

Keywords

  • Bioinformatics
  • Biomarkers
  • FT-ICR
  • Mass spectrometry
  • Ovarian cancer
  • Serum
  • TOF

ASJC Scopus subject areas

  • Medicine(all)
  • Clinical Biochemistry

Cite this

@article{4e37ae76fd204e13966f2b5c61cd5f67,
title = "Discovery of ovarian cancer biomarkers in serum using NanoLC electrospray ionization TOF and FT-ICR mass spectrometry",
abstract = "Treatment of cancer patients is greatly facilitated by detection of the cancer prior to metastasis. One of the obstacles to early cancer detection is the lack of availability of biomarkers with sufficient specificity. With modern differential proteomic techniques, the potential exists to identify high specificity cancer biomarkers. We have delineated a set of protocols for the isolation and identification of serum biomarkers for ovarian cancer that exist in the low molecular weight serum fraction. After isolation of the low molecular weight fraction by ultrafiltration, the potential biomarkers are separated by reversed phase nano liquid chromatography. Detection via TOF or FT-ICR yields a data set for each sample. We compared stage III/TV ovarian cancer serum with postmenopausal age-matched controls. Using bioinformatics tools developed at Mayo, we normalized each sample for intensity and chromatographic alignment. Normalized data sets are subsequently compared and potential biomarkers identified. Several candidate biomarkers were found. One of these contains the sequence of fibrinopeptide-A known to be elevated in many types of cancer including ovarian cancer. The protocols utilized will be examined and would be applicable to a wide variety of cancers or disease states.",
keywords = "Bioinformatics, Biomarkers, FT-ICR, Mass spectrometry, Ovarian cancer, Serum, TOF",
author = "Bergen, {Harold Robert (Bob) III} and George Vasmatzis and Cliby, {William Arthur} and Johnson, {Kenneth L.} and Oberg, {Ann L} and Muddiman, {David C.}",
year = "2003",
language = "English (US)",
volume = "19",
pages = "239--249",
journal = "Disease Markers",
issn = "0278-0240",
publisher = "IOS Press",
number = "4-5",

}

TY - JOUR

T1 - Discovery of ovarian cancer biomarkers in serum using NanoLC electrospray ionization TOF and FT-ICR mass spectrometry

AU - Bergen, Harold Robert (Bob) III

AU - Vasmatzis, George

AU - Cliby, William Arthur

AU - Johnson, Kenneth L.

AU - Oberg, Ann L

AU - Muddiman, David C.

PY - 2003

Y1 - 2003

N2 - Treatment of cancer patients is greatly facilitated by detection of the cancer prior to metastasis. One of the obstacles to early cancer detection is the lack of availability of biomarkers with sufficient specificity. With modern differential proteomic techniques, the potential exists to identify high specificity cancer biomarkers. We have delineated a set of protocols for the isolation and identification of serum biomarkers for ovarian cancer that exist in the low molecular weight serum fraction. After isolation of the low molecular weight fraction by ultrafiltration, the potential biomarkers are separated by reversed phase nano liquid chromatography. Detection via TOF or FT-ICR yields a data set for each sample. We compared stage III/TV ovarian cancer serum with postmenopausal age-matched controls. Using bioinformatics tools developed at Mayo, we normalized each sample for intensity and chromatographic alignment. Normalized data sets are subsequently compared and potential biomarkers identified. Several candidate biomarkers were found. One of these contains the sequence of fibrinopeptide-A known to be elevated in many types of cancer including ovarian cancer. The protocols utilized will be examined and would be applicable to a wide variety of cancers or disease states.

AB - Treatment of cancer patients is greatly facilitated by detection of the cancer prior to metastasis. One of the obstacles to early cancer detection is the lack of availability of biomarkers with sufficient specificity. With modern differential proteomic techniques, the potential exists to identify high specificity cancer biomarkers. We have delineated a set of protocols for the isolation and identification of serum biomarkers for ovarian cancer that exist in the low molecular weight serum fraction. After isolation of the low molecular weight fraction by ultrafiltration, the potential biomarkers are separated by reversed phase nano liquid chromatography. Detection via TOF or FT-ICR yields a data set for each sample. We compared stage III/TV ovarian cancer serum with postmenopausal age-matched controls. Using bioinformatics tools developed at Mayo, we normalized each sample for intensity and chromatographic alignment. Normalized data sets are subsequently compared and potential biomarkers identified. Several candidate biomarkers were found. One of these contains the sequence of fibrinopeptide-A known to be elevated in many types of cancer including ovarian cancer. The protocols utilized will be examined and would be applicable to a wide variety of cancers or disease states.

KW - Bioinformatics

KW - Biomarkers

KW - FT-ICR

KW - Mass spectrometry

KW - Ovarian cancer

KW - Serum

KW - TOF

UR - http://www.scopus.com/inward/record.url?scp=3042840116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042840116&partnerID=8YFLogxK

M3 - Article

C2 - 15266667

AN - SCOPUS:3042840116

VL - 19

SP - 239

EP - 249

JO - Disease Markers

JF - Disease Markers

SN - 0278-0240

IS - 4-5

ER -